Standard treatment is: rifampicin 10 mg/kg po plus streptomycin 15 mg/kg IM once daily for 8 weeks (RS8)
For early ulcers, may be able to do an oral regimen of rifampicin 10 mg/kg po plus clarithromycin ER 15 mg/kg po daily for 8 weeks (RC8)1
References
^Richard O Phillips, Jérôme Robert, Kabiru Mohamed Abass, William Thompson, Fred Stephen Sarfo, Tuah Wilson, Godfred Sarpong, Thierry Gateau, Annick Chauty, Raymond Omollo, Michael Ochieng Otieno, Thaddaeus W Egondi, Edwin O Ampadu, Didier Agossadou, Estelle Marion, Line Ganlonon, Mark Wansbrough-Jones, Jacques Grosset, John M Macdonald, Terry Treadwell, Paul Saunderson, Albert Paintsil, Linda Lehman, Michael Frimpong, Nanaa Francisca Sarpong, Raoul Saizonou, Alexandre Tiendrebeogo, Sally-Ann Ohene, Ymkje Stienstra, Kingsley B Asiedu, Tjip S van der Werf, Samuel Osei Mireku, Justice Abotsi, Joseph Ken Adu Poku, Richard Asamoah-Frimpong, Bright Osei-Wusu, Edward Sarpong, Beatrice Konadu, Ernest Opoku, Mark Forson, Mathias Ndogyele, Elizabeth Ofori, Felicity Aboagye, Thomas Berko, George Amofa, Anastasia Nsiah, Joyce Mensah-Bonsu, Joseph Ofori Nyarko, Yaw Ampem Amoako, Elliot Koranteng Tannor, Justice Boakye-Appiah, Aloysius Dzibordzi Loglo, Mabel Sarpong-Duah, Bernadette Agbavor, Marie Françoise Ardent, Arnaud Yamadjako, Naomi Adanmado Gersande, Ambroise Adeye, Martial Kindjinou, Akpolan, Maxime Kiki, Espoir Sodjinou, Clémence Guegnard, Sandor-Adrian Klis, Kristien Velding, Till Omansen, David Ofori-Adjei, Sarah Eyangoh, Alan Knell, William Faber. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. The Lancet. 2020. doi:10.1016/s0140-6736(20)30047-7.
